407 related articles for article (PubMed ID: 24590270)
1. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
4. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
Seltzer MJ; Bennett BD; Joshi AD; Gao P; Thomas AG; Ferraris DV; Tsukamoto T; Rojas CJ; Slusher BS; Rabinowitz JD; Dang CV; Riggins GJ
Cancer Res; 2010 Nov; 70(22):8981-7. PubMed ID: 21045145
[TBL] [Abstract][Full Text] [Related]
6. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
7. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
[TBL] [Abstract][Full Text] [Related]
9. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
10. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
12. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
[TBL] [Abstract][Full Text] [Related]
13. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of glioma and IDH1/IDH2 mutations.
Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
[TBL] [Abstract][Full Text] [Related]
16. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
19. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
